Monday, March 31, 2014 7:30:10 AM
I have actually a good feeling of approval for this drug. Seems that a drug ("Sonazoid") with the same active substance (perflubutane) has been approved by the Japanese FDA in 2007 and expanded for detection use of breast cancer in 2012
(http://www.firstwordmedtech.com/node/936259?tsid=17)
Imagify was first in application for USA and Europe, so big chance their Acusphere's product get's approved first.
Also GE Healthcare is marketing this drug in Japan, so if AI-700 get's approved in USa and/or Europe, Acusphere would become an interesting buy out target for them IMO.
Here also annual sales figures from Japan in 2010 and 2011 (bear in mind that in Europe and US cardiavascualair disease is more common):
http://www.evaluategroup.com/Universal/View.aspx?type=Entity&entityType=Product&id=15100&lType=modData&componentID=1002
Greetings Tanja
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM